Teijin Pharma's Feburic approved in Japan for chemo-induced hyperuricemia

23 May 2016

Japanese drugmaker Teijin Pharma (TYO: 3401) has received approval from the Ministry of Health, Labor and Welfare in its home country for Feburic (febuxostat) as a treatment for hyperuricemia caused by cancer chemotherapy.

Febuxostat, a novel drug developed for the treatment of hyperuricemia with or without gout, is currently sold in 57 countries and is set to be made available in 117 markets in regions including North America, Europe and Asia.

It is marketed as Adenuric in Europe, where it was approved in April 2015 for the prevention and treatment of hyperuricemia in adult patients undergoing chemotherapy for hematologic malignancies at intermediate to high risk of tumor lysis syndrome (TLS).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK